In order to further clarify the potential mechanism of CGFC-mediated CHSGS in treating depression, we compared and analyzed the pathways enriched by CGFC targets and pathogenic genes and found that 17 of the top 30 pathways were overlapped (Figure 7), and among these 17 pathways, the cAMP signaling pathway (HSA 04024), dopaminergic synapse (HSA 04728), PI3K-Akt signaling pathway (HSA 04151), and MAPK signaling pathway (HSA 04010) are widely reported to be related to the pathogenesis and treatment of depression. This evidence concerns the gene AKT1 and depressive symptom measurement.